Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADXN 
Addex Therapeutics Ltd (ADXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: ADXN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -10.28% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.85M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 11367 | Beta 1.91 | 52 Weeks Range 6.67 - 27.90 | Updated Date 03/31/2025 |
52 Weeks Range 6.67 - 27.90 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 912.4% | Operating Margin (TTM) -1066.38% |
Management Effectiveness
Return on Assets (TTM) -75.64% | Return on Equity (TTM) -168.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3791282 | Price to Sales(TTM) 13.25 |
Enterprise Value 3791282 | Price to Sales(TTM) 13.25 | ||
Enterprise Value to Revenue 6.04 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 1068950 | Shares Floating 34263843 |
Shares Outstanding 1068950 | Shares Floating 34263843 | ||
Percent Insiders - | Percent Institutions 1.41 |
Analyst Ratings
Rating 4 | Target Price 30 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Addex Therapeutics Ltd
Company Overview
History and Background
Addex Therapeutics Ltd is a pharmaceutical company focusing on developing novel allosteric modulators for neurological disorders. Founded in 2002, it has progressed through various clinical trials and partnerships to advance its pipeline.
Core Business Areas
- mGlu Receptor Allosteric Modulators: Development of oral, small molecule allosteric modulators targeting metabotropic glutamate (mGlu) receptors for diseases such as dystonia, schizophrenia, and epilepsy.
- GABAB Receptor Allosteric Modulators: Research and development of GABA<sub>B</sub> receptor positive allosteric modulators (PAMs) for the treatment of Charcot-Marie-Tooth disease 1A (CMT1A) and other neurological disorders.
Leadership and Structure
The company is led by a management team with expertise in drug discovery and development. The organizational structure includes research, clinical development, and business development departments.
Top Products and Market Share
Key Offerings
- Dipraglurant: Dipraglurant (ADX47273) is a negative allosteric modulator (NAM) of mGlu5 receptor being developed for treatment of dystonia. The market share varies but represents a significant portion of the dystonia drug pipeline. Competitors include established treatments like Botox and other developing therapies from companies like Neurocrine Biosciences and Revance Therapeutics.
- ADX71441: ADX71441 is a GABA<sub>B</sub> receptor positive allosteric modulator (PAM) is being developed for Charcot-Marie-Tooth disease 1A (CMT1A). The CMT1A market is currently underserved so the product offers a substantial potential market share. Competitors are currently very limited but gene therapies may present future competition.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurological disorders is competitive and characterized by high R&D costs and regulatory hurdles. Key trends include personalized medicine, gene therapy, and innovative drug delivery systems.
Positioning
Addex Therapeutics Ltd is positioned as a specialist in allosteric modulation, offering potentially more selective and tolerable treatments compared to traditional drugs. Their competitive advantage lies in their proprietary technology platform.
Total Addressable Market (TAM)
The combined TAM for the indications Addex is pursuing (dystonia, CMT1A and other CNS disorders) is in the billions of dollars. Addex is positioning itself to capture a share of this through its pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary allosteric modulation technology
- Strong preclinical and clinical data for lead compounds
- Experienced management team
- Partnerships with leading research institutions
Weaknesses
- Limited financial resources
- Dependence on partnering for late-stage development
- High risk associated with drug development
- Small market capitalization
Opportunities
- Potential for breakthrough therapies in neurological disorders
- Growing market for personalized medicine
- Increasing investment in CNS drug development
- Potential for strategic collaborations and licensing agreements
Threats
- Regulatory hurdles and clinical trial failures
- Competition from larger pharmaceutical companies
- Patent expirations
- Economic downturn affecting R&D investment
Competitors and Market Share
Key Competitors
- NBIX
- RVNC
- TEVA
Competitive Landscape
Addex's advantage lies in its allosteric modulator technology. However, it faces competition from larger pharmaceutical companies with greater resources and established market presence.
Major Acquisitions
No acquisitions to report
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: There have been no acquisitions for this organization
Growth Trajectory and Initiatives
Historical Growth: Addex's growth has been driven by clinical trial progress and strategic partnerships. The company has experienced periods of significant stock price volatility.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline compounds. Analyst estimates are not uniformly available due to its smaller size and focus.
Recent Initiatives: Recent initiatives include advancing clinical trials for Dipraglurant and ADX71441, and exploring new collaborations.
Summary
Addex Therapeutics is a specialized pharmaceutical firm with a novel approach to neurological disorders via allosteric modulation. Its success hinges on the advancement of its pipeline and strategic partnerships. However, limited resources and competition from larger companies pose challenges. The company's technology and focused approach present opportunities for growth. Addex needs to secure further funding and demonstrate clinical success to thrive.
Similar Companies
- NBIX
- RVNC
- TEVA
- ITCI
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (where applicable)
- Industry Reports
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance may change. Financial data may be limited due to the company being listed on the Swiss Exchange first and then on the OTC in the US.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Addex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-01-29 | Co-Founder, CEO & Director Mr. Timothy Mark Dyer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | |
Full time employees 23 | |||
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.